Drug Profile
Niclosamide - Ala Wai Pharma Australia
Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Ala Wai Pharma Australia
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Zika-virus-infection in Australia (PO, Tablet)
- 30 Jul 2019 Chemical structure information added